A meta-analysis based on 25 randomised controlled trials including 3,069 cancer patients showed that the use of erythropoietin significantly reduced the relative risk of red blood cell transfusion (RR 0.67, 95% CI: 0.62, 0.73) [9]. The gene discussed is EPO; the disease is cancer.